General Counsel Fisher Andrew sold 80,000 shares of VRNA at $11.52 on 2025-06-16, retaining 360.0K shares post-transaction.
Fisher Andrew, General Counsel of Verona Pharma, sold 80,000 shares at $11.52 on 2025-06-16, reducing his holdings by 18.2% to 359,999 shares. The company reported $76.3M in latest quarterly revenue against a net loss of $16.3M and remains unprofitable on a full-year basis. The current stock price of $90.92 is 30-day +25.3% and 90-day +37.2% above the transaction date, suggesting the sale preceded a significant appreciation period. Prior trades in this insider's cross-ticker history show 1 prior open-market sell with a 30d return of +975.8%, indicating a pattern where his sells have been followed by gains rather than declines. This transaction represents a material disposition by a senior executive of an unprofitable biotech concern during a period of strong positive momentum, though the underlying fundamentals remain challenged by ongoing losses.
General Counsel Andrew Fisher sells 80,000 VRNA shares at $8.57; stock up 22.3% in 30 days post-sale; company unprofitable.
Fisher Andrew, General Counsel, sold 80,000 shares (80.0K shares) of Verona Pharma plc at $8.57 on 2025-05-15, reducing his holdings by 18.2% from 440.0K shares to 360.0K shares. The sale occurred in a context of strong recent price momentum: the stock has risen 22.3% over the prior 30 days and is currently trading at $71.31, far above the sale price. Critically, the company remains unprofitable with a net income of $-16.3M in its most recent full fiscal year, while generating only $76.3M in quarterly revenue. The timing of a significant insider reduction—occurring well before the current price spike—suggests the transaction predates the recent momentum, making it difficult to infer conviction either way from price action alone.
